Work

Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2

Year: 2008

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2008.26.15_suppl.8516

Authors: B. Barlogie, E. J. Anaissie, F. van Rhee, J. D. Shaughnessy, J. Haessler, M. Pineda-Roman, K. Hollmig, J. Epstein, J. J. Crowley

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2530813851

Cites:

Cited by: 6

Related to: 10